Blog

The Pan Canadian Expert Review Committee has recommended the funding of pomalidomide (Pomalyst) for patients with relapsed and/or refractory multiple ...

[:content [\A \f \l \i \b \e \r \c \e \p \t \space \( \Z \a \l \t \r \a \p \) \  \i \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \e \d \space \f \o \r \space \u \s \e \space \w \i \t \h \i \n \space \N \H \S \space \S \c \o \t \l \a \n \d \space \f \o \r \space \u \s \e \  \i \n \space \c \o \m \b \i \n \a \t \i \o \n \space \w \i \t \h \space \i \r \i \n \o \t \e \c \a \n \/ \5 \- \f \l \u \o \r \o \u \r \a \c \i \l \/ \f \o \l \i \n \i \c \space \a \c \i \d \space \( \F \O \L \F \I \R \I \) \space \c \h \e \m \o \t \h \e \r \a \p \y \, \space \a \f \l \i \b \e \r \c \e \p \t \space \i \s \space \i \n \d \i \c \a \t \e \d " ..."]]

Effective April 1, 2015, the pCODR office will be moving to a new location in downtown Toronto -just a few ...

[:content [\N \I \C \E \space \h \a \s \space \i \s \s \u \e \d \  \n \e \w \space \p \r \e \l \i \m \i \n \a \r \y \space \g \u \i \d \a \n \c \e \  \t \h \a \t \space \d \o \e \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \space \P \f \i \z \e \r \' \s \space \b \o \s \u \t \i \n \i \b \space \( \B \o \s \u \l \i \f \) \space \f \o \r \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \p \r \e \v \i \o \u \s \l \y \space \t \r \e \a \t \e \d \space \c \h \r \o \n \i \c \space \m \y \e \l \o \i \d \space \l \e \u \k \a \e \m \i \a \space \( \C \M \L \) \. \  \B \o \s \u \t \i \n \i \b \space \i \s " ..."]]

People in Quebec living with chronic lymphocytic leukaemia (CLL) will now be able to access a new treatment option through the province's ...

[:content [\C \e \l \l \space \T \h \e \r \a \p \e \u \t \i \c \s \space \( \C \T \I \) \space \h \a \s \  \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \t \h \e \space \N \I \C \E \  \h \a \s \space \n \o \t \i \f \i \e \d \space \C \T \I \space \a \n \d \space \i \s \s \u \e \d \space \a \space \s \t \a \t \e \m \e \n \t \space \o \n \space \i \t \s \space \w \e \b \s \i \t \e \space \s \t \a \t \i \n \g \space \t \h \a \t \space \C \T \I \' \s \space \p \r \o \p \o \s \e \d " ..."]]

[:content [\B \o \e \h \r \i \n \g \e \r \space \I \n \g \e \l \h \e \i \m \space \( \C \a \n \a \d \a \) \space \L \t \d \. \space \h \a \s \space \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \G \i \o \t \r \i \f \  \( \a \f \a \t \i \n \i \b \) \space \t \a \b \l \e \t \s \space \f \o \r \space \o \r \a \l \space \u \s \e \, \space \a \s \space \a \space \n \e \w \space \t \r \e \a \t \m \e \n \t " ..."]]

[:content [\P \e \r \t \u \z \u \m \a \b \space \( \P \e \r \j \e \t \a \) \  \w \a \s \space \l \a \u \n \c \h \e \d \space \i \n \space \G \e \r \m \a \n \y \space \i \n \  \M \a \r \c \h \space \2 \0 \1 \3 \space \f \o \r \space \u \s \e \  \a \s \space \a \d \j \u \n \c \t \i \v \e \space \t \h \e \r \a \p \y \space \b \y \space \c \e \r \t \a \i \n \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \a \d \v \a \n \c \e \d \  \H \E \R \2 \- \p \o \s \i \t \i \v \e \space \b \r \e \a \s \t \space \c \a \n \c \e \r \. \  " ..."]]

CADTH is inviting stakeholders to attend an information and feedback session on 5 February 2015 regarding phase II of the ...

Merck Canada Inc. announced today that Keytruda (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. ...

[:content [\2 \1 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \â \€ \“ \space \E \f \f \e \c \t \i \v \e \space \1 \5 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \, \space \B \r \i \t \i \s \h \space \C \o \l \u \m \b \i \a \space \i \s \space \t \h \e \space \f \i \r \s \t \space \p \r \o \v \i \n \c \e \space \i \n \space \C \a \n \a \d \a \  \t \o \space \i \n \c \l \u \d \e \space \Z \y \t \i \g \a \  \( \a \b \i \r \a \t \e \r \o \n \e \space \a \c \e \t \a \t \e \) \space \o \n " ..."]]

Aprecia Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug ...

Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma, Inc., announced today that Health Canada has approved a ...